Feature Article

Intensive lipid-modifying therapy: why, when, who and how?




Because of issues related to the efficacy, safety and cost effectiveness of lipid-modifying drugs, physicians have a challenge to ensure these drugs are prescribed for the correct patient at the right time and in the correct manner. Patients have some responsibility to assist in this process, often in the face of an adverse lay media environment.

Key Points

  • Intensive lipid-modifying therapy is strongly indicated for all instances of secondary cardiovascular disease prevention alongside management of other conventional risk factors.
  • Less intensive lipid-modifying therapy is indicated for primary cardiovascular prevention in selected patients with high cardiovascular risk.
  • Low-density lipoprotein (LDL)-cholesterol targets are necessary and are generally attainable with appropriate therapy.
  • Adverse events sometimes occur in patients receiving intensive lipid-modifying therapy, for a variety of reasons, and require careful and sensitive management.

    Picture credit: © Freshidea/stock.adobe.com